Lilly and Vertex Pharmaceuticals Select Novel Oral Antihepatitis C Compound
First Announcement of Hepatitis C Protease Inhibitor Designated as Development Candidate
08-Jan-2002 -
Eli Lilly and Company and Vertex Pharmaceuticals Incorporated, announced today that they have selected LY570310 (VX-950), a novel small molecule protease inhibitor for the potential treatment of hepatitis C virus (HCV) infection, as a development candidate. The compound is the first drug ...
cirrhosis
clinical trials
drug development
+10